Skip to content

Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic pulmonary fibrosis (IPF) is the most common type of pulmonary fibrosis. It is a disease that causes scarring (fibrosis) of the lungs. The word “idiopathic” means it has no known cause. Scarring causes stiffness in the lungs and makes it difficult to breathe. Lung damage from IPF is irreversible and progressive. 

An investigator initiated, randomized, double-blind, placebo-controlled Phase 2 clinical trial with setanaxib in patients with idiopathic pulmonary fibrosis is currently in progress.

Potential for late-stage trial in IPF based on Ph2 signal.

Full data readout expected in 2H 2024.